Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment

van Herpen, Carla M.L.a; Lassen, Ulrikc; Desar, Ingrid M.E.a; Brown, Kathryn H.d; Marotti, Marcelod; de Jonge, Maja J.A.b

doi: 10.1097/CAD.0b013e32835bd1d2

Vascular endothelial growth factor (VEGF) signalling plays a key role in tumour angiogenesis. Cediranib (AZD2171) is a small-molecule VEGF signalling inhibitor with potent activity against all three VEGF receptors. In this phase I, open-label, parallel-group study, adults with advanced solid tumours received a single 45 mg dose of cediranib, followed by 30 mg continuous once-daily oral dosing for 21 days after a 7-day washout period ( identifier NCT00621725). The primary objective was to compare the single-dose pharmacokinetics (PK) of cediranib in patients with different levels of hepatic impairment classified according to the bilirubin level. Safety, tolerability, multiple-dose PK and PK stratified according to the Child–Pugh criteria were also assessed. Thirty patients received cediranib: 18 with normal–mild hepatic impairment and 12 with moderate hepatic impairment. Single-dose PK parameters were similar between the group with normal–mild hepatic impairment and the group with moderate hepatic impairment [ratio of geometric least square means: area under the curve (AUC) 1.12, 90% confidence interval (CI) 0.77–1.61; Cmax 0.95, 90% CI 0.69–1.31]. Hepatic impairment did not influence PK results in multiple dosing. After continuous once-daily dosing, the geometric least square means ratio was 0.72 (90% CI 0.51–1.03) for AUCSS and 0.67 (90% CI 0.47–0.94) for CSS,max. Similar results were obtained when patients were classified for hepatic impairment according to the Child–Pugh criteria. There was no clear difference in the incidence or the severity of adverse events between hepatic impairment groups. Moderate hepatic impairment does not appear to affect the PK profile or the tolerability of cediranib. Dose adjustments are not necessary in this patient population.

aDepartment of Oncology, Radboud University Nijmegen Medical Centre, Nijmegen

bDepartment of Oncology, Erasmus Medical Centre, Rotterdam, The Netherlands

cDepartment of Oncology, Rigshospitalet, Copenhagen, Denmark

dAstraZeneca R&D, Macclesfield, UK

Correspondence to Carla M.L. van Herpen, Department of Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, Geert Grooteplein 8, Nijmegen 6525GA, The Netherlands Tel: +31 24 3610353; fax: +31 24 3540788; e-mail:

Received September 27, 2012

Accepted October 23, 2012

© 2013 Lippincott Williams & Wilkins, Inc.